Alora Pharmaceuticals, LLC announces the availability of Once-Daily Relexxii® for the treatment of Attention Deficit Hyperactivity Disorder (ADHD)
19 Dec 2023
Drug Approval
ALPHARETTA, Ga., Dec. 19, 2023 /PRNewswire/ -- Alora Pharmaceuticals, LLC, the parent company of Vertical Pharmaceuticals, LLC, announced today the commercial availability of Relexxii® (methylphenidate hydrochloride extended-release tablets). Relexxii is a once-daily central nervous system (CNS) stimulant indicated for the treatment of Attention Deficit Hyperactivity Disorder (ADHD) in adults (up to the age of 65 years) and in pediatric patients 6 years of age and older.1 With the introduction of Relexxii, patients and health care professionals will have an additional branded ADHD treatment option from which to choose.
Continue Reading
Once-daily Relexxii is now widely available in flexible dosing options that support a more tailored treatment approach throughout the ADHD treatment journey: 18-mg, 27-mg, 36-mg, 45-mg, 54-mg, 63-mg, and 72-mg. This line of once-daily strengths has been specifically designed to support targeted titration to help achieve the lowest effective dose and to help mitigate the need for multiple daily pills. Once-daily Relexxii strengths are offered in 9-mg increments, yielding two "in-between" doses of 45-mg and 63-mg.
Available in flexible dosing options that support a more tailored treatment throughout the ADHD treatment journey.
Post this
Relexxii once-daily dosing is made possible by Alora Pharmaceutical's Osmodex® Drug Delivery Technology, which allows the medication to be released at a controlled rate throughout the day. With the immediate-release drug layer dissolving within one hour of administration, patients get the medicine they need quickly — and for up to 24 hours — with each daily dose.
"Alora Pharmaceuticals recognizes the importance of reliability when it comes to ADHD medications. Our mission of manufacturing supply to address the nationwide shortage is unwavering. With Relexxii, we can offer the consistency of a branded treatment for individuals affected by ADHD. Alora Pharmaceuticals remains committed to ensuring that patients have access to affordable medications that they need", stated Harold (Art) Deas, CEO of Alora Pharmaceuticals, LLC.
To learn more about Relexxii or to find patient support resources, please visit www.relexxii.com. For Full Prescribing Information, including BOXED WARNING, please visit www.relexxii.com/pi.
Alora Pharmaceuticals, LLC is the parent company of six specialty pharmaceutical and pharmaceutical manufacturing companies. Headquartered in Alpharetta, GA, Alora is the parent company of the following organizations that comprise the Alora Family of Companies: Avion Pharmaceuticals, Acella Pharmaceuticals, Osmotica Pharmaceuticals, Sovereign Pharmaceuticals, Trigen Laboratories, and Vertical Pharmaceuticals.
For media inquiries or for more information about Alora's efforts to address the nationwide ADHD treatment supply shortage, please contact Alora Pharmaceuticals, LLC: 1880 McFarland Parkway, Suite 110, Alpharetta, GA 30005; 1-678-325-5189.
www.alorapharma.com
Relexxii® is a registered trademark of Vertical Pharmaceuticals, LLC.
Osmodex® is a registered trademark of Acella Holdings, LLC.
Concerta® is a registered trademark of ALZA Corporation.
References: 1. Relexxii (methylphenidate hydrochloride extended-release tablets) package insert. Vertical Pharmaceuticals, LLC; 2023. 2. Data on file, Osmotica Pharmaceuticals US LLC.
SOURCE Alora Pharmaceuticals , LLC
For more details,please visit the original website
The content of the article does not represent any opinions of Synapse and its affiliated companies. If there is any copyright infringement or error, please contact us, and we will deal with it within 24 hours.
Targets
-Hot reports
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Leverages most recent intelligence information, enabling fullest potential.